Prescribing information

 

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

In the first update to the BAD chronic urticaria guidelines since 2007, join Dr John Reed and Dr Chris Rutowski (dermatology and allergy experts respectively) for their views on what they mean for your day-to-day practice.

Use the links below to jump to the individual videos:

1. BAD guidelines for CSU: A summary and why they matter

2. How do I choose between Xolair and ciclosporin?

3. Do I need to test total IgE & BHRA before putting patients onto Xolair?

4. How do you progress CSU patients through antihistamine?

5. Initiating Xolair in your trust for the first time

6. Should I be concerned about anaphylaxis?

7. What are the best PROs to use and when?

 

High-dose antihistamines and ciclosporin are not licensed for the treatment of CSU.

 

A review of the new BAD guidelines for CSU and how they can be used to support up-dosing or switching to second-line treatment more quickly.

 
 

Click here for Xolair® (omalizumab) prescribing information

When to prescribe omalizumab over ciclosporin, and vice versa, for the second-line treatment of CSU, using specific patient markers to identify appropriate treatment.

 
 

Click here for Xolair® (omalizumab) prescribing information

An exploration of the value of testing IgE and BHRA before prescribing omalizumab versus delaying treatment. 

 
 

Click here for Xolair® (omalizumab) prescribing information

How quickly to up-dose antihistamine, when high-dose antihistamine is not enough, and why monitoring patient response is key to decision making.

 
 

Click here for Xolair® (omalizumab) prescribing information

The steps to initiating omalizumab, emphasising the importance of patient-recorded outcome measures, reviewing patient response and stopping treatment where necessary.

 
 

Click here for Xolair® (omalizumab) prescribing information

A discussion of reported anaphylactic reactions in patients on omalizumab and the lack of evidence of this side effect in practice.

 
 

Click here for Xolair® (omalizumab) prescribing information

A review into the value of PROs and when to use them to support CSU treatment management decisions.

 
 

Click here for Xolair® (omalizumab) prescribing information

*Post hoc analysis of phase 3 studies2, omalizumab 300 mg significantly improved total DLQI scores vs placebo: ASTERIA I: mean decrease from baseline to week 12 of −10.3 vs −6.1 (p<0.0001); ASTERIA II: −10.2 vs −6.1 (p=0.0004); GLACIAL: −9.7 vs −5.1 (p<0.0001).

BAD, British Association of Dermatologists; BHRA: basophil histamine release assay; CSU: chronic spontaneous urticaria; IgE: immunoglobulin E; PRO: patient-reported outcome.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
Rate this content: 
No votes yet
UK | June 2022 | 221825
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]